Cyclooxygenase-2 Inhibitors

This publication has 176 references indexed in Scilit:

• Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis
  The American Journal of Cardiology, 2002
• Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
  JAMA, 2000
• The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
  Bioorganic & Medicinal Chemistry Letters, 1999
• Selective induction of cyclo‐oxygenase‐2 activity in the permanent human endothelial cell line HUV‐EC‐C: biochemical and pharmacological characterization
  British Journal of Pharmacology, 1997
• Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
  Nature, 1996
• Up‐regulation of cyclooxygenase‐2 mRNA in the rat spinal cord following peripheral inflammation
  FEBS Letters, 1996
• Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis
  The Journal of Clinical Pharmacology, 1995
• Prostaglandin endoperoxide synthase: regulation of enzyme expression
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1991
• Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence
  FEBS Letters, 1988
• FDA arthritis advisory committee meeting: Postmarketing surveillance of nonsteroidal antiinflammatory drugs
  Arthritis & Rheumatism, 1985